Mesoblast Share Price and Company Fundamentals
Last traded: Today at 12:15 AM
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
|Primary activities||A biotechnology company in the area of adult stem cell technology.|
|Industry / Sector||Biotechnology / Healthcare|
|Full time employees||83|
|Mailing address||55 Collins Street Level 38 Melbourne VIC 3000 Australia|
|Phone / Fax||61 3 9639 6036 / 61 3 9639 6030|
|Share registry||LINK MARKET SERVICES LIMITED|
Mesoblast paid $0.00 dividend and the ex-dividend date was .The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.MSB dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
MSB's forward dividend amount is $ and the forward dividend yield is . A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.
As of Aug 2022, following are the company executives and directors listed on Mesoblast.
|Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)||Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director||64||1.45M|
|Mr. Peter T. Howard B.Sc., L.L.B., BSc, LLB (Hons)||Gen. Counsel & Corp. Exec.||53|
|Mr. Michael Schuster M.B.A., MS, BSc, MBA||Head of Pharma Partnering||44|
|Dr. Eric A. Rose M.D.||Chief Medical Officer & Director||70||128.25k|
|Ms. Geraldine Storton B.Sc., M.B.A., Bsc, MMS, MBA||Head of Regulatory Affairs & Quality Management|
|Dr. Fred Grossman D.O., FAPA||Advisor|
|Mr. Andrew Chaponnel B.Com.||Interim Chief Fin. Officer|
|Ms. Dagmar Rosa-Bjorkeson M.B.A., M.S.||Chief Operating Officer||57|
|Mr. Roger D. Brown BA||Head of Spinal Orthopedic Disorders|
|Dr. Paul J. Simmons BSc, Ph.D.||Head of Research & New Product Devel.||62|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Mesoblast is and its enterprise value is .
The MSB's stocks Beta value is 2.57 making it 157% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Mesoblast (MSB)
Mesoblast (ASX:MSB) Frequently Asked Questions
1. What is Mesoblast's Stock Symbol?
Mesoblast trades on ASX under the ticker symbol "MSB".
2. What is Mesoblast's stock price today?
One share of MSB stock can currently be purchased for approximately $0.92.
3. How can I contact Mesoblast?
Mesoblast's mailing address is 55 Collins Street Level 38 Melbourne VIC 3000 Australia. The company can be reached via phone at 61 3 9639 6036.
4. What is Mesoblast's official website?
The official website of Mesoblast is https://www.mesoblast.com.
5. Which share registry manages Mesoblast's stock?
Mesoblast's stock is managed by LINK MARKET SERVICES LIMITED.